National Healthcare Corp
NHC NYSE Services-Skilled Nursing Care Facilities Financials FY2016βFY2025
What National Healthcare Corp does
No business description yet.
- Legal name
- NATIONAL HEALTHCARE CORP
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 26, 2026
- Accession Β· CIK
- 0001437749-26-005910
0001047335
Revenue and margins
National Healthcare Corp had $1.5B of revenue in fiscal 2025, up 16.1% on the year before.
Net income and earnings per share
From fiscal 2016 to 2025, diluted EPS grew 9.8% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $149M in fiscal 2025, 9.8% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
National Healthcare Corp returned $53.4M to shareholders in fiscal 2025, 36% of free cash flow. The diluted share count rose 0.3%.
Balance sheet
Cash, debt and the ratios that show how comfortably National Healthcare Corp can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $108M | $58.7M | $107M | $76.1M | $92.8M |
| Debt incl. finance leases | β | β | $0.9M | $137M | $40.0M |
| Net debt / EBITDA | β | β | β1.1x | 0.5x | β0.3x |
| Debt / equity | β | β | 0.0x | 0.1x | 0.0x |
| Interest coverage | 60.3x | 56.7x | 177.3x | 21.7x | 20.1x |
| Current ratio | 1.6x | 1.8x | 1.9x | 1.8x | 1.8x |
| Quick ratio | 1.6x | 1.8x | 1.9x | 1.8x | 1.8x |
| Total assets | $1.4B | $1.3B | $1.3B | $1.5B | $1.5B |
| Total liabilities | $495M | $398M | $400M | $541M | $452M |
| Shareholders' equity | $903M | $874M | $909M | $980M | $1.1B |
| Net debt (β = net cash) | β | β | β$106M | $60.9M | β$52.8M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 7 / 8 | 6 / 8 | 4 / 8 | 4 / 8 | 4 / 7 | 4 / 7 | 7 / 7 | 4 / 8 | 7 / 8 |
| Accruals ratio | β3.7% | β3.5% | β3.6% | β2.7% | β12.2% | 5.5% | 1.0% | β3.4% | β0.4% | β4.3% |
| Altman Z'' | 4.08 | 4.50 | 5.12 | 4.01 | 3.91 | 4.48 | 4.96 | 5.35 | 4.72 | 5.72 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $924M | $964M | $980M | $996M | $1.0B | $1.1B | $1.1B | $1.1B | $1.3B | $1.5B |
| Operating income | $60.5M | $54.1M | $56.1M | $49.0M | $48.2M | $50.9M | $31.9M | $57.5M | $89.9M | $128M |
| Interest expense | $3.9M | $4.9M | $4.7M | $3.1M | $1.4M | $0.8M | $0.6M | $0.3M | $4.1M | $6.4M |
| Pretax income | $80.2M | $74.5M | $74.9M | $88.0M | $52.4M | $150M | $27.2M | $88.7M | $136M | $162M |
| Income tax | $29.7M | $18.9M | $16.2M | $20.0M | $10.4M | $11.0M | $7.3M | $23.5M | $34.3M | $39.8M |
| Net income | $50.5M | $56.2M | $59.0M | $68.2M | $41.9M | $139M | $22.4M | $66.8M | $102M | $120M |
| Net income to common | $50.5M | $56.2M | $59.0M | β | β | β | β | β | β | β |
| Diluted EPS | $3.32 | $3.69 | $3.87 | $4.44 | $2.72 | $8.99 | $1.45 | $4.34 | $6.53 | $7.67 |
| Diluted shares | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B |
| Cash flow | ||||||||||
| Cash from operations | $90.9M | $94.5M | $98.4M | $100M | $203M | $62.4M | $8.7M | $111M | $107M | $185M |
| Capital expenditure | $62.6M | $32.3M | $29.8M | $26.4M | $21.9M | $39.4M | $30.2M | $27.9M | $27.6M | $36.4M |
| Free cash flow | $28.3M | $62.1M | $68.7M | $73.7M | $181M | $23.0M | β$21.5M | $83.3M | $79.7M | $149M |
| Depreciation and amortization | $39.0M | $42.7M | $41.9M | $42.4M | $42.0M | $40.7M | $40.5M | $42.0M | $42.0M | $44.9M |
| Stock-based compensation | $0.5M | $1.7M | $1.8M | $1.9M | $2.5M | $2.6M | $2.6M | $2.8M | $4.2M | $4.4M |
| Share buybacks | $8.2M | $0.0M | $0.9M | $0.9M | $0.1M | $0.8M | $9.9M | $2.5M | $13.5M | $14.7M |
| Dividends paid | $25.8M | $28.2M | $29.8M | $31.2M | $31.9M | $32.0M | $34.6M | $35.6M | $37.0M | $38.7M |
| Dividends and buybacks | $34.0M | $28.2M | $30.7M | $32.1M | $32.0M | $32.9M | $44.5M | $38.0M | $50.5M | $53.4M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $164M | $198M | $183M | $203M | $147M | $108M | $58.7M | $107M | $76.1M | $92.8M |
| Total debt | $120M | $100M | $55.0M | $10.0M | $0.0M | β | β | $0.0M | $137M | $40.0M |
| Finance lease liabilities | β | β | β | $19.1M | $15.0M | $10.5M | $5.8M | $0.9M | β | β |
| Current assets | $291M | $329M | $322M | $341M | $457M | $427M | $354M | $406M | $424M | $462M |
| Current liabilities | $151M | $155M | $158M | $195M | $281M | $263M | $198M | $214M | $235M | $254M |
| Inventory | $7.5M | $7.2M | $7.5M | $7.4M | $8.8M | $8.6M | $7.1M | $7.4M | $9.0M | $7.8M |
| Property and equipment, net | $560M | $549M | $535M | $535M | $520M | $521M | $507M | $493M | $684M | $674M |
| Goodwill | $17.6M | $17.6M | $21.0M | $21.0M | $21.3M | $168M | $168M | $168M | $170M | $170M |
| Intangible assets | β | β | β | β | $0.0M | $7.0M | $7.0M | $7.0M | $19.9M | $19.9M |
| Total assets | $1.1B | $1.1B | $1.1B | $1.3B | $1.4B | $1.4B | $1.3B | $1.3B | $1.5B | $1.5B |
| Total liabilities | $418M | $393M | $346M | $508M | $564M | $495M | $398M | $400M | $541M | $452M |
| Shareholders' equity | $670M | $703M | $733M | $779M | $795M | $903M | $874M | $909M | $980M | $1.1B |
| Margins | ||||||||||
| Operating margin | 6.6% | 5.6% | 5.7% | 4.9% | 4.7% | 4.7% | 2.9% | 5.0% | 6.9% | 8.5% |
| EBITDA margin | 10.8% | 10.0% | 10.0% | 9.2% | 8.8% | 8.5% | 6.7% | 8.7% | 10.1% | 11.4% |
| Net margin | 5.5% | 5.8% | 6.0% | 6.8% | 4.1% | 12.9% | 2.1% | 5.9% | 7.8% | 7.9% |
| FCF margin | 3.1% | 6.4% | 7.0% | 7.4% | 17.6% | 2.1% | β2.0% | 7.3% | 6.1% | 9.8% |
| Returns | ||||||||||
| Return on capital | 6.3% | 6.7% | 7.3% | 6.5% | 6.0% | β | β | 5.3% | 6.5% | 9.5% |
| Return on capital employed | 6.5% | 5.7% | 6.1% | 4.5% | 4.5% | 4.5% | 3.0% | 5.2% | 7.0% | 10.1% |
| Return on equity | 7.5% | 8.2% | 8.2% | 9.0% | 5.3% | 16.3% | 2.5% | 7.5% | 10.8% | 11.7% |
| Return on assets | 4.6% | 5.1% | 5.4% | 5.8% | 3.2% | 10.0% | 1.7% | 5.2% | 7.2% | 7.9% |
| Return on tangible equity | 7.8% | 8.2% | 8.3% | 9.0% | 5.4% | 19.0% | 3.2% | 9.1% | 12.9% | 13.7% |
| Growth | ||||||||||
| Revenue growth | β | 4.4% | 1.7% | 1.6% | 3.2% | 4.5% | 1.1% | 5.1% | 14.5% | 16.1% |
| Net income growth | β | 11.2% | 4.9% | 15.7% | β38.6% | 231.0% | β83.8% | 197.6% | 52.6% | 17.7% |
| EPS growth | β | 11.1% | 4.9% | 14.7% | β38.7% | 230.5% | β83.9% | 199.3% | 50.5% | 17.5% |
| FCF growth | β | 119.6% | 10.5% | 7.3% | 146.1% | β87.3% | β193.3% | β | β4.3% | 86.5% |
| Share count change | β | 0.1% | 0.1% | 0.8% | 0.1% | 0.3% | 0.2% | β0.5% | 1.4% | 0.3% |
| Financial health | ||||||||||
| Net debt / EBITDA | β0.4x | β1.0x | β1.3x | β1.9x | β1.5x | β | β | β1.1x | 0.5x | β0.3x |
| Debt / equity | 0.2x | 0.1x | 0.1x | 0.0x | 0.0x | β | β | 0.0x | 0.1x | 0.0x |
| Interest coverage | 15.4x | 11.1x | 11.9x | 15.6x | 34.4x | 60.3x | 56.7x | 177.3x | 21.7x | 20.1x |
| Current ratio | 1.9x | 2.1x | 2.0x | 1.8x | 1.6x | 1.6x | 1.8x | 1.9x | 1.8x | 1.8x |
| Quick ratio | 1.9x | 2.1x | 2.0x | 1.7x | 1.6x | 1.6x | 1.8x | 1.9x | 1.8x | 1.8x |
| Capital allocation | ||||||||||
| Capex / revenue | 6.8% | 3.4% | 3.0% | 2.6% | 2.1% | 3.7% | 2.8% | 2.4% | 2.1% | 2.4% |
| Stock comp / revenue | 0.1% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.3% | 0.3% |
| Payouts / FCF | 120.2% | 45.5% | 44.7% | 43.5% | 17.6% | 142.9% | β | 45.7% | 63.3% | 36.0% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 7.0 | 6.0 | 4.0 | 4.0 | 4.0 | 4.0 | 7.0 | 4.0 | 7.0 |
| Altman Z'' | 4.1 | 4.5 | 5.1 | 4.0 | 3.9 | 4.5 | 5.0 | 5.3 | 4.7 | 5.7 |
| Accruals ratio | β3.7% | β3.5% | β3.6% | β2.7% | β12.2% | 5.5% | 1.0% | β3.4% | β0.4% | β4.3% |
Source: SEC EDGAR XBRL filings (CIK 0001047335). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.